Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HBV-infected Primary Human Hepatocytes and HBV-infected HepG2-NTCP cells treatment by Interferon subtypes

ABSTRACT: HBV-infected Primary Human Hepatocytes and HBV-infected HepG2-NTCP cells treatment by Interferon subtypes

PROVIDER: PRJNA576399 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq analysis of HBV-infected HepG2-NTCP cells treated by Interferon subtypes

Project description:Examination of interferon stimulated genes treated with different kind of interferon subtypes in HBV-infected HepG2-NTCP cells.

2020-04-20 | GSE138567 | GEO

RNA-seq analysis of HBV-infected HepG2-NTCP cells treated by Interferon subtypes

Project description:RNA-seq analysis of HBV-infected HepG2-NTCP cells treated by Interferon subtypes

| PRJNA576398 | ENA

Transcriptome profiles of Huh7.5.1-NTCP cells treated with HBV preS1 peptide

Project description:Chronic hepatitis B, C and D virus (HBV, HCV, HDV) infections are leading causes of liver disease and cancer worldwide. Although these viruses differ markedly in their life cycle and genomic organization, they exclusively infect hepatocytes. Recently, the sodium taurocholate cotransporting polypeptide (NTCP) was identified as the first functional receptor for HBV and HDV. Here, we report that NTCP also facilitates HCV entry into human hepatocytes, by augmenting the bile acid-mediated repression of IFN-stimulated genes (ISGs), including IFITM2 and IFITM3, to increase the susceptibility of cells to HCV entry. Furthermore, an HBV-derived preS1 peptide, known to bind NTCP and to inhibit bile acid uptake and HBV infection, inhibits HCV entry by enhancing the expression of ISGs. Our study highlights NTCP as a novel player linking bile acid metabolism to the interferon response in hepatocytes and establishes a role for NTCP in the entry process of multiple hepatotropic viruses, via distinct mechanisms. Collectively, these findings enhance our understanding of hepatitis virus-host interactions and suggest NTCP as an attractive antiviral target for HBV/HCV co-infection. Transcriptome profiling by DNA microarray of Huh7.5.1 cells transduced to express NTCP.

2016-10-25 | E-GEOD-79089 | biostudies-arrayexpress

Transcriptomic alteration after miR-6126 tranfection into HepG2-NTCP

Project description:Aim: Hepatitis B virus (HBV) infection is one of the most serious global health problems. Our previous study revealed that an increase in the miR-6126 serum level over one year of pegylated interferon therapy predicted a decrease in hepatitis B surface (HBs) antigens. We aimed to clarify whether miR-6126 downregulated the expression level of sodium taurocholate cotransporting polypeptide (NTCP), a host cell receptor required for HBV entry. Methods: HepG2-NTCP and PXB cells were utilized to evaluate the expression level of NTCP after transfection with miR-6126. The protein expression level of NTCP was evaluated using Western blot analysis and immunostaining. The expression profile of messenger RNAs was evaluated using next-generation sequencing to search for direct targets of miR-6126.

2021-12-28 | GSE192617 | GEO

Transcriptome profiles of Huh7.5.1-NTCP cells treated with HBV preS1 peptide

2016-10-25 | GSE79089 | GEO

Expression data from HepG2-NTCP and Huh-106 cell lines

Project description:Microarray data to compare the gene expression in HepG2-NTCP and Huh-106 cell lines Knowledge of HBV virus-host interactions is still limited. Here, we performed a genome-wide gain-of-function screen using weakly permissive Huh-106 cells to uncover novel HBV host factors.

2020-04-21 | GSE132638 | GEO

Phosphoproteome profiling unravels rewiring of chromatin organization factors in host cells upon HBV infection

Project description:Hepatitis B virus (HBV) infection leads tdevelopment of fatal liver complications. Due to a lack of effective measure to cure HBV infection, complete eradication of HBV is difficult. Thus, novel HBV therapeutic strategies are needed. Host proteins involved in the HBV infection processes are known to be regulated through phosphorylation. System level changes in phospho-signaling pathway in host during infection remains unclear. To this end, phosphoproteome profiling on HBV infected HepG2-NTCP cells was performed.

2022-06-09 | PXD015393 | Pride

HBV-infected Primary Human Hepatocytes and HBV-infected HepG2-NTCP cells treatment by Interferon subtypes

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-04-20 | GSE138569 | GEO

RNA Expression Profile of HBV-infected Primary Human Hepatocytes treatment by Interferon subtypes.

Project description:Microarray-dependent transcriptional analysis of interferon stimulated genes treated with different kind of interferon subtypes in HBV-infected PHH.

2020-04-20 | GSE138566 | GEO

Transcriptome profiles of primary human hepatocytes treated with HBV preS1 peptide with or without bile acids

Project description:Chronic hepatitis B, C and D virus (HBV, HCV, HDV) infections are leading causes of liver disease and cancer worldwide. Although these viruses differ markedly in their life cycle and genomic organization, they exclusively infect hepatocytes. Recently, the sodium taurocholate cotransporting polypeptide (NTCP) was identified as the first functional receptor for HBV and HDV. Here, we report that NTCP also facilitates HCV entry into human hepatocytes, by augmenting the bile acids-mediated repression of IFN-stimulated genes (ISGs), including IFITM2 and IFITM3, to increase the susceptibility of cells to HCV entry. Furthermore, an HBV-derived preS1 peptide, known to bind NTCP and to inhibit bile acids uptake and HBV infection, inhibits HCV entry by enhancing the expression of ISGs. Our study highlights NTCP as a novel player linking bile acids metabolism to the interferon response in hepatocytes and establishes a role for NTCP in the entry process of multiple hepatotropic viruses, via distinct mechanisms. Collectively, these findings enhance our understanding of hepatitis virus-host interactions and suggest NTCP as an attractive antiviral target for HBV/HCV co-infection.

2016-10-25 | GSE85091 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data